William G. Wierda, MD, PhD

References

Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib [published online February 7, 2017]. Cancer. doi: 10.1002/cncr.30596. Jain N, Basu S, Thompson PA, et al. Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial. 58th ASH Annual Meeting and Exposition; San Diego, California; December 2-6, 2016. Abstract 59.

Patients with chronic lymphocytic leukemia (CLL) who stopped treatment with ibrutinib for toxicities had longer survival than those who discontinued for other reasons, including progression and Richter transformation (RT), as reported in a study published in the journal Cancer.Median survival was 33 months for patients who discontinued ibrutinib (Imbruvica) because of intolerance/toxicities, 16 months for progressive disease, and 11 months for those who discontinued for miscellaneous reasons. Median survival was just 2.3 months in patients who developed RT (P